Canaccord Genuity Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $6
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Edward Nash maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $7 to $6.
Canaccord Genuity analyst Edward Nash maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $7 to $6.